Short Interest in Humacyte, Inc. Declines by 42%

Biotech company's stock sees drop in short positions amid ongoing clinical trials for its lead vascular implant candidate.

Jan. 30, 2026 at 1:55pm

Got story updates? Submit your updates here. ›

Humacyte, Inc. (NASDAQ:HUMAW), a clinical-stage biotechnology company developing human acellular vessels (HAVs) for vascular access and other applications, saw a significant 42% decrease in short interest on its stock in January. The short-interest ratio now stands at 0.2 days based on the company's average daily trading volume.

Why it matters

Fluctuations in short interest can provide insights into investor sentiment and market expectations around a company's prospects. The decline in short positions on Humacyte suggests growing optimism among some investors about the potential of the company's lead HAV product candidate as it advances through clinical trials.

The details

As of January 15th, Humacyte had short interest totaling 2,478 shares, down from 4,269 shares at the end of December 2025 - a 42% decrease. The company's average daily trading volume is 14,761 shares, putting the current short-interest ratio at 0.2 days.

  • Humacyte reported the short interest data as of January 15, 2026.
  • The previous short interest data point was as of December 31, 2025.

The players

Humacyte, Inc.

A clinical-stage biotechnology company developing human acellular vessels (HAVs) for vascular access, peripheral artery disease, and other applications.

Got photos? Submit your photos here. ›

What’s next

Humacyte is expected to provide updates on the progress of its HAV clinical trials in the coming months, which could further impact short interest and investor sentiment around the company's prospects.

The takeaway

The decline in short interest on Humacyte's stock suggests growing optimism among some investors about the potential of the company's lead vascular implant product as it advances through clinical development. However, the stock remains highly volatile, underscoring the need for continued monitoring of the company's progress.